RANK and RANKL expression in giant-cell tumour of bone

The Lancet Oncology

Volumn 11, Issue 6, 2010, Pages 514-

  Roux, Sophie ^a   Mariette, Xavier ^b  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

CANCER RESEARCH; CARCINOGENESIS; CELL CULTURE; GENE OVEREXPRESSION; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LETTER; MESENCHYME CELL; MONONUCLEAR CELL; OSTEOCLAST; OSTEOCLASTOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 77953484235     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70076-0     Document Type: Letter

References (5)

1. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010, 11:275-280.
2. Atkins GJ, Haynes DR, Graves SE, et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 2000, 15:640-649.
3. Huang L, Xu J, Wood DJ, et al. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 2000, 156:761-767.
4. Atkins GJ, Bouralexis S, Haynes DR, et al. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone 2001, 28:370-377.
5. Roux S, Amazit L, Meduri G, et al. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol 2002, 117:210-216.